What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Immune system
Barry G. W. Arnason spends much of his time researching Internal medicine, Multiple sclerosis, Immunology, Endocrinology and Pathology.
The study incorporates disciplines such as Surgery, Expanded Disability Status Scale and Pharmacology in addition to Internal medicine.
His Multiple sclerosis study combines topics from a wide range of disciplines, such as Gastroenterology, Molecular biology, Cerebrospinal fluid and Cytokine.
His research combines Central nervous system and Immunology.
His Endocrinology research is multidisciplinary, incorporating elements of Receptor, Immune system and Sensitization.
His Pathology research is multidisciplinary, incorporating perspectives in Acute motor sensory axonal neuropathy, Acute motor axonal neuropathy, Cell mediated immunity and Peripheral nerve.
His most cited work include:
- THE INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITIS (606 citations)
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (351 citations)
- Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial (337 citations)
What are the main themes of his work throughout his whole career to date?
Barry G. W. Arnason focuses on Immunology, Multiple sclerosis, Internal medicine, Endocrinology and Antibody.
Immunology is a component of his Immune system, Antigen, Encephalomyelitis, Experimental allergic and Histocompatibility studies.
His Multiple sclerosis study incorporates themes from Cerebrospinal fluid, Disease, Pathology and Central nervous system disease.
His biological study spans a wide range of topics, including Gastroenterology, In vitro, Surgery and Interferon beta-1b.
His studies in Endocrinology integrate themes in fields like Concanavalin A, Receptor, Nerve growth factor and Neuroblastoma.
In his research on the topic of Antibody, Monoclonal antibody is strongly related with Molecular biology.
He most often published in these fields:
- Immunology (42.24%)
- Multiple sclerosis (29.96%)
- Internal medicine (28.52%)
What were the highlights of his more recent work (between 2001-2019)?
- Multiple sclerosis (29.96%)
- Internal medicine (28.52%)
- Immunology (42.24%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Multiple sclerosis, Internal medicine, Immunology, Interferon beta-1b and Antibody.
His Multiple sclerosis research is multidisciplinary, relying on both Disease and Oncology.
His Internal medicine research includes themes of Gastroenterology, Surgery and Expanded Disability Status Scale.
His Immunology research incorporates elements of Myelin, Myelin basic protein and Virology.
His research integrates issues of Nuclear medicine and Pharmacology in his study of Interferon beta-1b.
His Antibody research integrates issues from Receptor, Nucleic acid, Interferon and Molecular biology.
Between 2001 and 2019, his most popular works were:
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study (351 citations)
- Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial (337 citations)
- Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci (268 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Immune system
His main research concerns Multiple sclerosis, Internal medicine, Glatiramer acetate, Expanded Disability Status Scale and Clinical trial.
His research on Multiple sclerosis concerns the broader Immunology.
His research in Immunology is mostly concerned with Immune system.
Barry G. W. Arnason focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Surgery and, in certain cases, Gastroenterology, Secondary progressive multiple sclerosis, Neurology and Drug.
Within one scientific family, he focuses on topics pertaining to Interferon beta-1b under Glatiramer acetate, and may sometimes address concerns connected to Follow up studies, Treatment outcome and Post hoc.
His work carried out in the field of Expanded Disability Status Scale brings together such families of science as Clinical endpoint and Randomized controlled trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
